Transfusion-associated graft versus host disease (TA-GVHD) is a. prevented through leukoreduction ...

Author Question: Transfusion-associated graft versus host disease (TA-GVHD) is a. prevented through leukoreduction ... (Read 70 times)

joblessjake

Hero Member
Posts: 555

on: Jun 25, 2018

Transfusion-associated graft versus host disease (TA-GVHD) is

a. prevented through leukoreduction
b. almost universally fatal
c. caused by engraftment of donor B lymphoctyes
d. most often diagnosed in immunocompetent patients

Question 2

Which of the following is an oral iron chelator?

a. Deferasirox
b. Deferoxamine
c. Dexamethasone
d. Dimercaprol

eliasc0401

Sr. Member
Posts: 338

Reply #1 on: Jun 25, 2018

Answer to Question 1

Answer: b

Answer to Question 2

Answer: a

Need homework help now?

Ask unlimited questions for free

Ask a Question

« previous next »

Did you know?

Signs and symptoms that may signify an eye tumor include general blurred vision, bulging eye(s), double vision, a sensation of a foreign body in the eye(s), iris defects, limited ability to move the eyelid(s), limited ability to move the eye(s), pain or discomfort in or around the eyes or eyelids, red or pink eyes, white or cloud spots on the eye(s), colored spots on the eyelid(s), swelling around the eyes, swollen eyelid(s), and general vision loss.

Did you know?

The shortest mature adult human of whom there is independent evidence was Gul Mohammed in India. In 1990, he was measured in New Delhi and stood 22.5 inches tall.

Did you know?

Vaccines cause herd immunity. If the majority of people in a community have been vaccinated against a disease, an unvaccinated person is less likely to get the disease since others are less likely to become sick from it and spread the disease.

Did you know?

The use of salicylates dates back 2,500 years to Hippocrates's recommendation of willow bark (from which a salicylate is derived) as an aid to the pains of childbirth. However, overdosage of salicylates can harm body fluids, electrolytes, the CNS, the GI tract, the ears, the lungs, the blood, the liver, and the kidneys and cause coma or death.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.